TD Cowen Maintains Buy on Boston Scientific, Lowers Price Target to $56

Benzinga Newsdesk www.benzinga.com Negative 66.5%

Neg 66.5% Neu 0% Pos 0%

TD Cowen analyst Joshua Jennings maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $61 to $56.